These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27506789)

  • 1. QnAs with James Allison.
    Nair P
    Proc Natl Acad Sci U S A; 2016 Aug; 113(33):9131-2. PubMed ID: 27506789
    [No Abstract]   [Full Text] [Related]  

  • 2. Somatic mutations and immunotherapy outcome with CTLA-4 blockade in melanoma.
    Boussiotis VA
    N Engl J Med; 2014 Dec; 371(23):2230-2. PubMed ID: 25409261
    [No Abstract]   [Full Text] [Related]  

  • 3. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma.
    Chan TA; Wolchok JD; Snyder A
    N Engl J Med; 2015 Nov; 373(20):1984. PubMed ID: 26559592
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune modulation in cancer with antibodies.
    Page DB; Postow MA; Callahan MK; Allison JP; Wolchok JD
    Annu Rev Med; 2014; 65():185-202. PubMed ID: 24188664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy.
    Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671754
    [No Abstract]   [Full Text] [Related]  

  • 6. Genetic basis for clinical response to CTLA-4 blockade.
    Melero I; Lasarte JJ
    N Engl J Med; 2015 Feb; 372(8):783. PubMed ID: 25693025
    [No Abstract]   [Full Text] [Related]  

  • 7. Genetic basis for clinical response to CTLA-4 blockade.
    Snyder A; Wolchok JD; Chan TA
    N Engl J Med; 2015 Feb; 372(8):783. PubMed ID: 25693024
    [No Abstract]   [Full Text] [Related]  

  • 8. Skin cancer. Benefiting from CTLA-4 blockade--a genetic rationale.
    Errico A
    Nat Rev Clin Oncol; 2015 Jan; 12(1):4. PubMed ID: 25488393
    [No Abstract]   [Full Text] [Related]  

  • 9. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
    Camacho LH
    Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and Emerging Perspectives on Immunotherapy for Melanoma.
    Daud A
    Semin Oncol; 2015 Dec; 42 Suppl 3():S3-S11. PubMed ID: 26598057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma drug wins US approval.
    Ledford H
    Nature; 2011 Mar; 471(7340):561. PubMed ID: 21455150
    [No Abstract]   [Full Text] [Related]  

  • 13. Aflibercept, ipilimumab, and vemurafenib.
    Hussar DA; Au AY
    J Am Pharm Assoc (2003); 2012; 52(2):291-4. PubMed ID: 22370387
    [No Abstract]   [Full Text] [Related]  

  • 14. How should we use anti-CTLA-4 antibodies?
    Marabelle A; Eggermont A
    Eur J Cancer; 2015 Nov; 51(17):2686-8. PubMed ID: 26613660
    [No Abstract]   [Full Text] [Related]  

  • 15. Facing the dawn of immunotherapy for hepatocellular carcinoma.
    Sprinzl MF; Galle PR
    J Hepatol; 2013 Jul; 59(1):9-10. PubMed ID: 23571018
    [No Abstract]   [Full Text] [Related]  

  • 16. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future directions for checkpoint inhibition in melanoma.
    Hamid O
    Clin Adv Hematol Oncol; 2016 Feb; 14(2):85-6. PubMed ID: 27057805
    [No Abstract]   [Full Text] [Related]  

  • 18. Immune checkpoint blockade in patients with melanoma metastatic to the brain.
    Di Giacomo AM; Margolin K
    Semin Oncol; 2015 Jun; 42(3):459-65. PubMed ID: 25965364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [When CRAF takes over BRAF in melanoma].
    Dumaz N; Bagot M; Bensussan A
    Med Sci (Paris); 2011 Oct; 27(10):817-9. PubMed ID: 22027417
    [No Abstract]   [Full Text] [Related]  

  • 20. Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy.
    Felix J; Cassinat B; Porcher R; Schlageter MH; Maubec E; Pages C; Baroudjian B; Homyrda L; Boukouaci W; Tamouza R; Bagot M; Caignard A; Toubert A; Lebbé C; Moins-Teisserenc H
    Int Immunopharmacol; 2016 Nov; 40():466-473. PubMed ID: 27728898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.